Age-related macular degeneration, or "AMD" for short, has serious effects on vision. It leads to the loss of sensory cells at the point of sharpest vision in the retina. There are two forms of AMD: dry, in which vision deteriorates gradually, and wet (exudative), which is characterized by rapid loss of central vision. Today, there are treatment options for certain forms of the disease. However, these are only effective if therapy is given early.
A causal treatment of dry AMD is currently not possible.
In the treatment of wet AMD, the new anti-VEGF therapy can inhibit the growth of newly formed vessels under the site of sharpest vision by introducing an antibody into the vitreous. By binding the antibody to the growth factor, initiated vessel growth is stopped, the vessels stick together and the swelling of the tissue decreases. In this injection into the vitreous body (intravitreal injection), the antibody is injected into the eye. The treatment is repeated several times and must be performed over a longer period of time. With this new method, visual acuity can be maintained in the vast majority of cases, and even improved in some cases.